1032 results
The “twin cycles” of diabetes, first introduced by Roy Taylor in 2008.  
#fatty liver #fatty
pancreas #diabetes #t2d ... #dm2 #insulin resistance ... #pathophysiology
A1C and eAG
~
*For Educational Purposes Only*

#Diabetes #T2D #DM2 #Table #PrimaryCare #Endocrinology #BloodGlucose #A1C
#Diabetes #T2D ... #DM2 #Table #PrimaryCare
Patient factors influencing the selection Of glucose-lowering drugs Other than SGLT2i and metformin in T2D and
and metformin in T2D ... sulfonylurea; T2D ... type 2 diabetes; TZD ... type 2 diabetes; TZD
SGLT2 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits SGLT2 (sodium/glucose cotransporter 2) in the proximal tubule,
patients with T2D ... mL/minute/1.73 m2 ... Pharmacology #Summary #DM2
Estimating the Total Daily Dose (TDD) of Insulin: Weight-Based Dosing
TDD in units of insulin = N
Total Daily Dose (TDD ... Weight-Based Dosing TDD ... Calculate TDD 2 ... @DharSaty #TDD ... endocrinology #diabetes #DM2
Stages in the Development of Diabetes Type 1

#Diabetes #Type1 #TypeI #DM1 #Stages #Development #Pathophysiology #Timeline #Diagnosis
#Type1 #TypeI #DM1 ... #Development #Pathophysiology
Mechanism of Action for Common Diabetes Medications

 • SGLT2i (Dapagliflozin)
 • TZD (Pioglitazone)
 • Biguanides (Metformin)
Dapagliflozin) • TZD ... #pharmacology #pathophysiology
Pathophysiology of Diabetic Ketoacidosis (DKA) and Hyperglycemic Hyperosmolar Syndrome (HHS)
Absolute Insulin deficit:
 - Type I DM:
Pathophysiology ... deficit: - Type I DM ... produced - Type II DM ... #dka #hhs #pathophysiology
Metformin Pharmacology Summary
Mechanisms of Action:
 • Suppresses gluconeogenesis by the liver
 • Increases insulin-mediated glucose utilization
mL/minute/1.73 rm2 ... mL/minute/1.73 m2 ... Pharmacology #Summary #DM2
Profiles of Antidiabetic Medications - AACE 2018 

#Antidiabetic #Medications #Profiles #SideEffects #Table #DecisionAid #Orals #DM2 #Diabetes
DecisionAid #Orals #DM2